StockData
Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc. (ARCT) stock

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)

Close on Nov 17, 2026Market cap $226.53MP/E –Yield –

Arcturus Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Arcturus Therapeutics's pe ratio was 8.9× on Jan 31, 2024.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 20248.9×+0.4
2023Dec 29, 20238.5×–

More Arcturus Therapeutics figures

See a number that looks wrong?